MKC-1

DB05608InvestigationalSmall molecule

Investigated for use/treatment in breast cancer, leukemia (unspecified), lung cancer, and solid tumors.

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3, Vascular endothelial growth factor receptor 2, and Aurora kinase A
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer, leukemia (unspecified), lung cancer, and solid tumors.Curator reviewed
Formula / weight: C₂₂H₁₆N₄O₄ · 400.394 g/mol (avg)
Code names: RO 31-7453

Resolves to

Compound

Structure

InChIKeyOVSKGTONMLKNPZ-UHFFFAOYSA-NSMILESCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC(=CC=C12)[N+]([O-])=O

Targets

What you can answer from here — as of June 15, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with MKC-1, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.